EVGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evogene Ltd (EVGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak financial performance, no significant positive trading signals, and limited catalysts for growth in the near term. While the company has a promising AI discovery engine and collaborations, its financials and technical indicators suggest caution.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral, and the moving averages are bearish, with SMA_200 above SMA_20 and SMA_5. The stock is trading near its pivot level of 0.812, with resistance at 0.888 and support at 0.736. Overall, the technical indicators suggest a mixed to bearish trend.
Gross margin increased by 25.88% YoY in the latest quarter.
There is no recent news or significant trading trends from hedge funds, insiders, or Congress. Analysts have lowered the price target from $2.50 to $1.75.
In Q4 2025, revenue dropped significantly to $314,000 (-80.51% YoY), net income fell to -$5,309,000 (-1343.33% YoY), and EPS declined to -0.61 (-1116.67% YoY). However, gross margin improved to 66.88% (+25.88% YoY).
Analysts maintain a Buy rating but have lowered the price target from $2.50 to $1.75, citing the company's focus on its AI discovery engine and collaborations. However, the financial outlook remains weak, and the cash balance is expected to last until 2H27.
